女性健康投资展望：近50%人口仅获得6%资金——不仅是缺口，更是未开发的空白领域

I N S I G H TR E P O R T Contents Foreword Executive summary Introduction 1 Case study: IVF1.1 Proof of scale: investment and market maturity1.2 Where the investment flowed, and where gaps remain 2 The Women’s Health Investment Index11 2.1 The investment gap in women’s health2.2 Signals of investor success1316 3 Areas prime for investment 3.1 Women’s cancer therapeutics3.2 Virtual women’s healthcare and benefits management3.3 Remote maternal health monitoring 4 Call to action Conclusion34 Appendix A: Methodology Appendix B: Additional figures Contributors Endnotes 42 Disclaimer This document is published by the World Economic Forum as acontribution to a project, insight area or interaction. The findings,interpretations and conclusions expressed herein are a result ofa collaborative process facilitated and endorsed by the World ©2026 World Economic Forum. All rights reserved. No part ofthis publication may be reproduced or transmitted in any form orby any means, including photocopying and recording, or by any Foreword Shyam BishenHead, Centre for Healthand Healthcare; Member of Trish StromanManaging Directorand Senior Partner, Gender equality has advanced, yet the gapbetween health outcomes for men and womenremains substantial. Limited investment – alongsidedisparities in research design, clinical data andaccess to care – continues to entrench this divide. and consumer demand, are aligning to de-riskinnovation and attract capital. New ventures areredefining healthcare technology, data science The investment case is both empirical andcompelling: women drive most healthcare decisionsglobally and are central to household, communityand macroeconomic stability. A healthier population The macroeconomic case for women’s healthis increasingly clear. Targeted investment canstrengthen productivity, resilience and long-termgrowth. The returns are embedded in the coredrivers of economic performance: when women’s Achieving equity requires coordinated investmentin research that centres on women’s health; in sex-and gender-disaggregated data; in equitable access Momentum is building. Across sectors and assetclasses, investors are increasingly recognizing thatwomen’s health is no longer a niche segment butan undercapitalized growth frontier. Regulatory and This report provides an outlook on the women’shealth market – its scale, momentum, barriersand opportunities – and examines how capital, Executive summary Women’s health receives only 6% of privatehealthcare investment – a striking imbalancethat underscores both the magnitude of the Unfortunately, limited investment and the resultinglack of products and services that meet the needsof women and girls exacerbate health disparities.Women may live longer than men, yet spend25% more of their lives in poor health or with a Women’s health represents a large andundercapitalized opportunity in global healthcare.Despite women and girls representing nearly The fundamentals are strong, but funding remainslimited and narrowly focused, historically confined toreproductive and maternal health. This narrow focushas overlooked major areas of unmet need andopportunity across high-burden, high-prevalenceconditions that affect women uniquely, differentlyand disproportionately, such as cardiovascular To quantify private investment flows in women’shealthcare (including conditions that affect womenuniquely, differently and disproportionately) over the healthcare and benefits management; remotematernal health monitoring; women-focusedmental health platforms; women-first longevity andwellness concierge services; and wearable devices The analyses conducted for this report revealed: –Chronic underinvestment:Women’s healthreceives only 6% of private healthcare capital, What is needed now is targeted, multistakeholder –An early-stage market:50% of privateinvestment in women’s health-specific –Build a demand-driven evidence base with sex-specific research and real-world outcomes to –Capital concentration:80% of funding eventsand 90% of capital flow to three areas –reproductive health, maternal care and women’scancers, leaving significant white space in –Mobilize blended capital to bridge the –Modernize regulatory and clinical end-points to –Emerging horizontal, cross-therapeuticsolutions:Nearly half of women’s healthcompanies operate in cross-therapeutic or –Expand reimbursement to establish predictable –Encourage participation from adjacentincumbents with the capabilities to address –Geographic imbalance:North America andEurope dominate deal activity, while low-andmiddle-income countries (LMICs) are under- –Increase transparency on economic returnsand clinical outcomes to enable investors to –Proof of scale:The in vitro fertilization (IVF)market shows what is possible in women’shealth; when scientific reliability, reimbursementand policy align, a niche market can become a The business case for women’s health is clear andcompelling. Significant white